To investigate aqueous humor levels of 11 factors/cytokines in patients with central retinal vein occlusion (CRVO) and macular edema (ME) receiving anti-vascular endothelial growth factor (VEGF) therapy, as well as correlations between changes of functional or morphological parameters and aqueous cytokine levels.
Methods:
In 32 CRVO patients scheduled to receive 2 consecutive doses of intravitreal ranibizumab, aqueous samples were obtained at the time of injecting each dose. Aqueous levels of VEGF, soluble VEGF receptor (sVEGFR)-1, sVEGFR-2, platelet-derived growth factor-AA (PDGF-AA), placental growth factor (PlGF), interleukin-6, and monocyte chemotactic protein-1 (MCP-1) were measured using a suspension array.
Results:
Aqueous humor levels of VEGF, sVEGFR-1, PDGF, PlGF, interleukin-6, and MCP-1 were all significantly lower at 1 month after the initial dose of intravitreal ranibizumab compared with baseline. A significant negative correlation was noted between the change of ME and the changes of aqueous humor VEGF or interleukin-6 levels after intravitreal ranibizumab. The change of VEGF also showed a significant negative correlation with improvement of visual acuity.
Conclusions:
In patients with CRVO, the changes of visual acuity and ME after intravitreal ranibizumab were associated with inhibition of intraocular VEGF production. VEGF could be a useful marker for the response of ME to treatment.
Get full access to this article
View all access options for this article.
References
1.
NomaH., FunatsuH., MimuraT., HarinoS., and HoriS.Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 16:87–93, 2009.
2.
CampochiaroP.A., BrownD.M., AwhC.C., et al.Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 118:2041–2049, 2011.
3.
HeierJ.S., ClarkW.L., BoyerD.S., et al.Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 121:1414–1420.e1411, 2014.
4.
EghojM.S., and SorensenT.L.Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br. J. Ophthalmol. 96:21–23, 2012.
5.
NomaH., MimuraT., YasudaK., and ShimuraM.Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema. Invest. Ophthalmol. Vis. Sci. 56:1122–1128, 2015.
6.
KotakeO., NomaH., YasudaK., MotohashiR., GotoH., and ShimuraM.Comparing cytokine kinetics between ranibizumab and aflibercept in central retinal vein occlusion with macular edema. Ophthalmic. Res., 2018 [Epub ahead of print]; DOI: 10.1159/000488494.
7.
WenJ., JiangY., ZhengX., and ZhouY.Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion. Br. J. Ophthalmol. 99:1334–1340, 2015.
8.
ShchukoA.G., ZlobinI.V., IurevaT.N., OstaninA.A., ChernykhE.R., and MikhalevichI.M.Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy. Indian J. Ophthalmol. 63:905–911, 2015.
9.
NomaH., MimuraT., YasudaK., and ShimuraM.Possible molecular basis of bevacizumab therapy for macular edema in branch retinal vein occlusion. Retina. 36:1718–1725, 2016.
10.
NomaH., MimuraT., YasudaK., and ShimuraM.Cytokine kinetics after monthly intravitreal bevacizumab for retinal vein occlusion associated with macular oedema. Ophthalmic. Res. 56:207–214, 2016.
11.
ClarksonJ.G., ChuangE., GassD., et al.Baseline and early natural history report. The Central Vein Occlusion Study. Arch. Ophthalmol. 111:1087–1095, 1993.
12.
TsujikawaA., OguraY., HiroshibaN., MiyamotoK., KiryuJ., and HondaY.In vivo evaluation of leukocyte dynamics in retinal ischemia reperfusion injury. Invest. Ophthalmol. Vis. Sci. 39:793–800, 1998.
13.
ShibuyaM.Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2:1097–1105, 2011.
14.
TolentinoM.J., MillerJ.W., GragoudasE.S., et al.Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 103:1820–1828, 1996.
15.
CampochiaroP.A., WykoffC.C., ShapiroH., RubioR.G., and EhrlichJ.S.Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 121:1783–1789, 2014.
16.
BarleonB., SozzaniS., ZhouD., WeichH.A., MantovaniA., and MarmeD.Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:3336–3343, 1996.
17.
ClaussM., WeichH., BreierG., et al.The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem., 271:17629–17634, 1996.
18.
HiratsukaS., MinowaO., KunoJ., NodaT., and ShibuyaM.Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 95:9349–9354, 1998.
19.
MurakamiM., ZhengY., HirashimaM., et al.VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler. Thromb. Vasc. Biol. 28:658–664, 2008.
20.
KibaA., SagaraH., HaraT., and ShibuyaM.VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem. Biophys. Res. Commun. 301:371–377, 2003.
21.
MurakamiM., IwaiS., HiratsukaS., et al.Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood. 108:1849–1856, 2006.
22.
YuanJ., GuoQ., QureshiA.R., et al.Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. Nephrol. Dial. Transplant. 28:2356–2363, 2013.
23.
DiSalvoJ., BayneM.L., ConnG., et al.Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J. Biol. Chem. 270:7717–7723, 1995.
24.
YangX., ZhangY., YangY., et al.Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 110:13932–13937, 2013.
25.
HossainM.Z., AoP., and BoyntonA.L.Rapid disruption of gap junctional communication and phosphorylation of connexin43 by platelet-derived growth factor in T51B rat liver epithelial cells expressing platelet-derived growth factor receptor. J. Cell. Physiol. 174:66–77, 1998.
26.
MamerS.B., ChenS., WeddellJ.C., et al.Discovery of high-affinity PDGF-VEGFR interactions: redefining RTK dynamics. Sci. Rep. 7:16439, 2017.
27.
MarumoT., Schini-KerthV.B., FisslthalerB., and BusseR.Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation. 96:2361–2367, 1997.
28.
CuiH.S., HayasakaS., ZhangX.Y., HayasakaY., ChiZ.L., and ZhengL.S.Effect of berberrubine on interleukin-8 and monocyte chemotactic protein-1 expression in human retinal pigment epithelial cell line. Life Sci. 79:949–956, 2006.
WangL., KouM.C., WengC.Y., HuL.W., WangY.J., and WuM.J.Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF-kappaB, and MAPK pathways. Arch. Toxicol. 86:879–896, 2012.
31.
YinY., SiX., GaoY., GaoL., and WangJ.The nuclear factor-kappaB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinoma. Oncol. Rep. 29:34–38, 2013.
32.
YooS.A., BaeD.G., RyooJ.W., et al.Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J. Immunol. 174:5846–5855, 2005.
33.
AngeloL.S., and KurzrockR.Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin. Cancer Res. 13:2825–2830, 2007.
34.
DvorakH.F., BrownL.F., DetmarM., and DvorakA.M.Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029–1039, 1995.
35.
VinoresS.A., DerevjanikN.L., OzakiH., OkamotoN., and CampochiaroP.A.Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc. Ophthalmol. 97:217–228, 1999.
36.
GardnerT.W., AntonettiD.A., BarberA.J., LiethE., and TarbellJ.A.The molecular structure and function of the inner blood-retinal barrier. Penn State Retina Research Group. Doc. Ophthalmol., 97:229–237, 1999.
37.
CohenT., NahariD., CeremL.W., NeufeldG., and LeviB.Z.Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271:736–741, 1996.
38.
MaruoN., MoritaI., ShiraoM., and MurotaS.IL-6 increases endothelial permeability in vitro. Endocrinology. 131:710–714, 1992.
39.
NomaH., MinamotoA., FunatsuH., et al.Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes. Arch. Clin. Exp. Ophthalmol. 244:309–315, 2006.
40.
CampochiaroP.A., HafizG., MirT.A., et al.Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology. 122:1426–1437, 2015.
